TENAYA THERAPEUTICS
Tenaya Therapeutics is a developer of novel therapies designed to offer treatment for heart disease. The company's therapies address heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration, enabling physicians to regenerate heart tissue, and additional programs focused on cardiomyopathies.
TENAYA THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care Therapeutics
Founded:
2016-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.tenayatherapeutics.com
Total Employee:
11+
Status:
Active
Total Funding:
248 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Wordpress Plugins Global Site Tag
Similar Organizations
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Century Therapeutics
Century Therapeutics is a developer of allogeneic living drugs created to offer treatment for cancer.
Comet Therapeutics
Comet Therapeutics is a developer of therapies designed to treat orphan neurological disorders.
EIP Pharma
EIP Pharma Provides Healthcare Services.
Entrada Therapeutics
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Felix Biotechnology
Felix Biotechnology is working to accelerate the deployment of novel biotherapeutics to manage infectious diseases.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Nine Square Therapeutics
Nine Square Therapeutics is a developer of novel therapies for movement disorders.
Pipeline Therapeutics
Pipeline Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases.
PolyProx
PolyProx Therapeutics is a developer of a novel class of drug intended to provide new therapies for cancer treatment.
Rainier Therapeutics
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.
Relay Therapeutics
Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.
Skyhawk Therapeutics
Skyhawk Therapeutics is a provvider of small molecule therapeutics designed to offer therapies that correct RNA expression.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Vaxcyte
Vaxcyte focuses on developing vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.
Current Advisors List
Board_member
Board_observer
Current Employees Featured
Benoit Bruneau Co-Founder @ Tenaya Therapeutics
Co-Founder
2016-10-01
Tim Hoey Chief Scientific Officer @ Tenaya Therapeutics
Chief Scientific Officer
2017-08-01
Kathy Ivey Senior Director Gene Therapy Biology @ Tenaya Therapeutics
Senior Director Gene Therapy Biology
2020-02-01
Whit Tingley Chief Medical Officer @ Tenaya Therapeutics
Chief Medical Officer
2018-12-01
Sheng Ding Co-Founder @ Tenaya Therapeutics
Co-Founder
2016-10-01
Deepak Srivastava Scientific Co-Founder @ Tenaya Therapeutics
Scientific Co-Founder
Eric Olson Scientific Co-Founder @ Tenaya Therapeutics
Scientific Co-Founder
Bruce Conklin Co-Founder @ Tenaya Therapeutics
Co-Founder
2016-07-01
Faraz Ali Chief Executive Officer @ Tenaya Therapeutics
Chief Executive Officer
2018-06-01
Saptarsi Haldar Scientific Co-Founder @ Tenaya Therapeutics
Scientific Co-Founder
Founder
Stock Details
Investors List
T. Rowe Price
T. Rowe Price investment in Series C - Tenaya Therapeutics
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Series C - Tenaya Therapeutics
RTW Investments LLC
RTW Investments LLC investment in Series C - Tenaya Therapeutics
Casdin Capital
Casdin Capital investment in Series C - Tenaya Therapeutics
GV
GV investment in Series C - Tenaya Therapeutics
The Column Group
The Column Group investment in Series C - Tenaya Therapeutics
RA Capital Management
RA Capital Management investment in Series C - Tenaya Therapeutics
Casdin Capital
Casdin Capital investment in Series B - Tenaya Therapeutics
Greenspring Associates
Greenspring Associates investment in Series B - Tenaya Therapeutics
The Column Group
The Column Group investment in Series B - Tenaya Therapeutics
Official Site Inspections
http://www.tenayatherapeutics.com Semrush global rank: 10.19 M Semrush visits lastest month: 29
- Host name: 113.175.239.35.bc.googleusercontent.com
- IP address: 35.239.175.113
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Tenaya Therapeutics"
Investor Relations | Tenaya Therapeutics, Inc.
Dec 17, 2024 The Investor Relations website contains information about Tenaya Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
Leadership - Tenaya Therapeutics
Williams also served as the Chief Executive Officer of Gladstone Foundation, a not-for-profit organization supporting Gladstone Institutes from January 2016 to December 2018. Since …See details»
Tenaya Therapeutics - Crunchbase Company Profile
Tenaya Therapeutics is a developer of novel therapies designed to offer treatment for heart disease. The company's therapies address heart failure …See details»
Tenaya Therapeutics - LinkedIn
Tenaya Therapeutics is a clinical stage biotechnology company. The Company was founded in 2016 by leading cardiovascular scientists from the David J. Gladstone Institutes and the University of ...See details»
Our Science - Tenaya Therapeutics
We have internalized the ability to create and integrate proprietary in vitro and in vivo models within our research organization. For our in vitro hiPSC-CM disease models, we use multiple methods to induce phenotypes within cell lines that …See details»
Tenaya Therapeutics Overview | SignalHire Company Profile
Organization Website: tenayatherapeutics.com : Tenaya Therapeutics industries Biotech: Headquarters Location: 171 Oyster Point Blvd, South San Francisco, California, 94080 US …See details»
Tenaya Therapeutics Closes $92 Million Series B Financing | Tenaya ...
Oct 3, 2019 Headquartered in South San Francisco, California, Tenaya was founded by world-leading scientists from the Gladstone Institute’s Cardiovascular Division and from the …See details»
Tenaya Therapeutics (TNYA) Company Profile & Description
Jul 30, 2021 171 Oyster Point Boulevard, Suite 500 South San Francisco, California 94080 United StatesSee details»
Tenaya Therapeutics - VentureRadar
"Tenaya Therapeutics is a biopharmaceutical company with a mission to discover, develop, and deliver potentially curative treatments that target the underlying causes of heart disease.See details»
Tenaya Therapeutics - Craft
Tenaya Therapeutics has 1 employees at their 1 location. See insights on Tenaya Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
News Releases | Tenaya Therapeutics, Inc.
Jan 13, 2025 The Investor Relations website contains information about Tenaya Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
Tenaya Therapeutics - Overview, News & Similar companies
May 23, 2024 Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tenaya …See details»
Tenaya Therapeutics, Inc. (TNYA) - Yahoo Finance
Find the latest Tenaya Therapeutics, Inc. (TNYA) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Tenaya Therapeutics Receives $8 Million Clinical Grant from …
Feb 3, 2025 For more information, visit www.tenayatherapeutics.com. Forward Looking Statements This press release contains forward-looking statements as that term is defined in …See details»
Tenaya Therapeutics Announces 2025 Strategic Priorities and …
Jan 13, 2025 Tenaya Therapeutics, Inc. Continued Focus on Driving Advancement of TN-201 and TN-401 Gene Therapies for Cardiomyopathies. Dosing Initiated in Cohort 2 of the …See details»
Tenaya Therapeutics Announces Late Breaker Presentation of New …
2 days ago TN-201 Has Been Well Tolerated at 3E13 vg/kg Dose New Biopsy Data Reaffirm Robust Transduction and RNA Expression with TN-201; RNA and Protein Levels Increase …See details»
Tenaya Therapeutics Announces 2025 Strategic Priorities and …
Jan 13, 2025 Continued Focus on Driving Advancement of TN-201 and TN-401 Gene Therapies for Cardiomyopathies Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial …See details»
Our Programs - Tenaya Therapeutics
TN-201: MYBPC3 Gene Therapy Program for Genetic HCM. We are developing TN-201, an adeno-associated virus (AAV)-based gene therapy designed to treat adults and children with …See details»
Tenaya highlights HCM gene therapy interim data at ACC 2025
1 day ago In two out of the first three patients, TN-201 was able to increase MyBP-C protein levels from 56% to 59% in one, and 62% to 64% in the other after 52 weeks. Credit: …See details»
Tenaya Therapeutics to Highlight Growing Capabilities in Capsid ...
May 2, 2024 Tenaya also has multiple early-stage programs progressing through preclinical development. For more information, visit www.tenayatherapeutics.com. Forward-Looking …See details»